ImmunityBio experienced a notable upward rally marked by elevated trading activity, driven by robust buying interest across the commercial-stage oncology sector. Investor optimism continues to be fueled by strong commercial momentum surrounding its flagship immunotherapy, ANKTIVA, alongside steady regulatory and pipeline progress in global jurisdictions. Continued market adoption of ANKTIVA for non-muscle invasive bladder cancer, combined with supplemental regulatory filings and expanding international approvals, has significantly reinforced long-term growth expectations among institutional and retail investors alike.

In addition to core commercial traction, sentiment has been energized by strategic corporate developments within the…